G1 Therapeutics (NASDAQ:GTHX) had its target price cut by analysts at Needham & Company LLC from $76.00 to $74.00 in a report issued on Thursday. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a potential upside of 62.03% from the company’s previous close.
Other equities analysts have also issued reports about the company. Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Thursday, August 9th. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 11th. JPMorgan Chase & Co. raised their target price on G1 Therapeutics from $58.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, August 10th. BidaskClub upgraded G1 Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Finally, BTIG Research began coverage on G1 Therapeutics in a research report on Monday, September 10th. They issued a “buy” rating and a $80.00 price target on the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $74.00.
NASDAQ GTHX opened at $45.67 on Thursday. G1 Therapeutics has a fifty-two week low of $18.03 and a fifty-two week high of $69.57. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -12.79 and a beta of 1.16.
G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, November 7th. The company reported ($0.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. On average, equities research analysts anticipate that G1 Therapeutics will post -2.64 EPS for the current year.
In other news, VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $59.60, for a total value of $44,700.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jay Strum sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $59.60, for a total value of $596,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,583 shares of company stock worth $3,483,971. 15.92% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of GTHX. FMR LLC grew its position in G1 Therapeutics by 6.4% during the third quarter. FMR LLC now owns 5,216,663 shares of the company’s stock worth $272,780,000 after buying an additional 313,931 shares in the last quarter. BlackRock Inc. grew its position in G1 Therapeutics by 8.7% during the third quarter. BlackRock Inc. now owns 1,836,822 shares of the company’s stock worth $96,048,000 after buying an additional 146,462 shares in the last quarter. Bank of New York Mellon Corp grew its position in G1 Therapeutics by 1,497.7% during the second quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock worth $54,890,000 after buying an additional 1,183,940 shares in the last quarter. JPMorgan Chase & Co. grew its position in G1 Therapeutics by 16.6% during the third quarter. JPMorgan Chase & Co. now owns 530,979 shares of the company’s stock worth $27,765,000 after buying an additional 75,690 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its position in G1 Therapeutics by 34.8% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 474,433 shares of the company’s stock worth $24,808,000 after buying an additional 122,380 shares in the last quarter. 69.09% of the stock is currently owned by institutional investors.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Recommended Story: Do stock splits help investors?
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.